Neoantigen Vaccines Pass the Immunogenicity Test.


Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for precision therapies customized to each patient's tumor mutational profile. 
DOI: 10.1016/j.molmed.2017.08.007

1 Figure or Table


  • Presentations referencing similar topics